Biogen Inc.

NASDAQ Global Select
Back to all articles
Neutral 0

Morgan Stanley Remains a Hold on Biogen (BIIB)

📊 Morgan Stanley analyst Terence Flynn maintains a Hold rating on Biogen (BIIB) with a price target of $206.00.

🧑‍💼 Analyst Terence Flynn is ranked as a 5-star performer with an average return of 8.7% and a 55.65% success rate.

💼 Wedbush also issued a Hold rating on Biogen from analyst Laura Chico in a concurrent report released today.

🔥 Canaccord Genuity reiterated its Buy rating on Biogen, contrasting the recent hold recommendations.

💰 In Q1 ending March 31, Biogen reported quarterly revenue of $2.48 billion and net profit of $319.5 million.

📈 The company's Q1 net profit increased from $240.5 million in the previous year, while revenue rose from $2.43 billion.

⚠️ Corporate insider sentiment is currently negative due to a quarter-long increase in insider share sales.

🔻 Biogen Head of Development Priya Singhal recently sold 2,660 shares for approximately $531,548 in February 2026.

📉 Other analysts have adjusted their price targets upward, including Wedbush raising it to $196 and Guggenheim to $260.

Bullish Signals
  • Biogen reported a quarterly revenue of $2.48 billion, representing year-over-year growth from $2.43 billion in the same period last year.
  • The company's net profit increased to $319.5 million compared to $240.5 million last year, demonstrating strong bottom-line performance.
  • Canaccord Genuity reiterated a Buy rating on Biogen (NASDAQ: BIIB), signaling analyst confidence in the stock.
  • Wedbush raised its price target for Biogen to $196 from $191, indicating upside potential according to their latest analysis.
  • Guggenheim raised its price target for Biogen to $260 from $246, reflecting a bullish view on the company's prospects.
  • Bank of America increased its price target for Biogen to $203 from $200, further supporting the investment thesis.
  • Positive catalysts such as strong Q1 results, pipeline progress, and the Apellis deal are driving buy ratings across multiple analyst firms.
Risk Factors
  • Morgan Stanley maintained a 'Hold' rating with a price target of $206.00, indicating analysts see limited upside potential at current levels.
  • Wedbush's Laura Chico also issued a Hold rating on the same day, despite Canaccord Genuity maintaining a Buy, suggesting conflicting analyst sentiment.
  • Corporate insider sentiment is negative as over the past quarter there has been an increase in insiders selling their shares compared to earlier this year.
  • Head of Development Priya Singhal sold 2,660 shares for $531,547.80 in February 2026, contributing to negative insider activity signals.
  • The article notes that CNR shares are volatile, which poses a risk to short-term price stability.
Full Analysis
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB) with a price target of $206.00. According to TipRanks, analyst Flynn holds a 5-star rating with an average return of 8.7% and a success rate of 55.65%. He covers the Healthcare sector, including holdings in BioNTech SE, Biogen, and Vertex Pharmaceuticals. While Morgan Stanley maintained its stance, Wedbush's Laura Chico also issued a Hold recommendation on the same day, whereas Canaccord Genuity reiterated its Buy rating for the stock. Recent corporate data indicates mixed sentiment surrounding the company. Based on earnings released for the quarter ending March 31, Biogen reported quarterly revenue of $2.48 billion and net profit of $319.5 million, compared to previous year figures of $2.43 billion in revenue and $240.5 million in net profit. Despite these results, insider activity remains negative; corporate data from 33 insiders shows an increase in selling shares over the past quarter relative to earlier this year. Specifically, Priya Singhal, Head of Development, sold 2,660 shares for $531,547.80 in February 2026. Beyond Morgan Stanley's report, other financial institutions have adjusted their positions on Biogen. Wedbush raised its price target from $191 to $196, while Guggenheim increased its target to $260 from $246. Additionally, Bank of America raised its price target from $200 to $203 and assigned a Buy rating supported by strong Q1 results, pipeline progress, and the Apellis deal. These varying analyst opinions and internal trading activities continue to reflect divergent views on Biogen’s current trajectory and future potential.